Efferon therapy

15/03/2026

In Sepsis, Waiting for Lab Results Can Be Too Late

If new studies in hemoadsorption were designed, what should they focus on?

An ICU expert explains why timing may be the most critical factor in sepsis treatment, and why relying too heavily on laboratory tests might delay life-saving decisions.

Insights from the frontline of critical care, sepsis research, and medical innovation.

Follow for more discussions on next-generation therapies and the future of medicine.

13/03/2026

is one of the leading causes of acute kidney injury (S-AKI) in intensive care units.

When a patient develops septic shock, a massive release of , interleukins, pNGAL, reactive oxygen species disrupts microcirculation. The kidneys are starved of oxygen, leading to rapid cellular damage.

At Efferon, we believe in breaking this destructive cycle. helps stabilize hemodynamics and, most importantly, restore targeted renal perfusion.

Let's protect your !

12/03/2026

This , we are looking inside the ICU. When strikes, the body's own immune response can go into overdrive, shutting down microcirculation and starving the of oxygen.

Have a look how acts as a shield, restoring blood flow, and giving the kidneys the oxygen they need to recover (often saving from prolonged !)

12/03/2026

On 9-10 of March, Efferon participated in a pediatric conference hosted at Ospedale Pediatrico Bambino Gesù in Rome.

In many areas of critical care, treatment options for pediatric patients remain limited. Children require a specific focus, as they are not simply small adults and need treatment approaches adapted to their unique physiology and psychology.

, our new hemoadsorption device specifically designed for children, was presented at the conference and drew significant attention from leading Italian pediatric specialists.

This innovative technology provides access to extracorporeal blood purification for children with , and its effectiveness has been confirmed in a multicenter clinical study.

We would like to thank our partner Gada Italia by Palex Italia for the invitation and the opportunity to be part of this meaningful exchange.

11/03/2026

Efferon mówi „cześć” Polsce!

We are proud to announce that Efferon has received official authorization in Poland, making it the 42nd country worldwide and the 16th in the EU where our devices are available!

We are delighted to work with our partner West Medical. Their deep knowledge of the Polish healthcare system and long-standing experience in medical distribution will help bring Efferon directly to the clinicians and patients who need it most.

is a next-generation hemoadsorption device that targets both endotoxins and cytokines, helping to control the systemic inflammatory response in sepsis. With EU approval under the MDR, it offers clinicians a reliable tool to support critical patients when every hour counts.

We can’t wait to hear about the first clinical cases in and see how Efferon makes a difference for patients. Let’s keep moving forward!

10/03/2026

This March 8th, a pediatric intensivist Dr. Gabriella Bottari, shares her perspective on therapy in critically ill children: from decision-making in narrow therapeutic windows to the need for pediatric-specific extracorporeal solutions. While Efferon has transformed adult critical care, the pediatric setting still presents unique challenges and opportunities for innovation.

This International Women's Day 2026, we celebrate women in medicine and science, and their courage to innovate for better outcomes in pediatric intensive care.

Dr. Gabriella Bottari, pediatric intensivist, shares her perspective on the role of hemoadsorption therapy in critically ill children and the challenges of t...

09/03/2026

The 45-Minute Rule in Hemoadsorption That Could Change Sepsis Treatment

An ICU specialist Professor Ioannis Griveas explains why timing matters more than rigid protocols, and why starting early and ensuring enough treatment time can make a real difference for critically ill patients.

Insights from the frontline of critical care, sepsis treatment, and medical innovation.

Follow for more insights on next-generation therapies and critical care medicine.

05/03/2026

Is Hemoadsorption Becoming Essential in ICU?

Prof. Giannis Griveas shares his perspective on hemoadsorption in modern ICU practice.

In the evolving landscape of sepsis management, hemoadsorption is becoming a fundamental element — both as a standalone therapy and in combination with other critical care treatments.

What role should it play in today’s ICU protocols?

Follow us for more expert insights from leading intensivists across Europe.

04/03/2026

Meet Efferon at the International Symposium on Intensive Care and Emergency Medicine this March in Brussels.

From March 17–20, join us at Stand 2.25–2.28 at the SQUARE Brussels Meeting Centre. We will be presenting Efferon’s next-generation extracorporeal blood adsorbers for and septic shock, designed and manufactured in the European Union.

We are also excited to give a first glimpse of our upcoming solution, designed to expand the benefits of Efferon’s blood purification technology.

We look forward to meaningful conversations, new connections, and the opportunity to meet colleagues face to face in Brussels.

03/03/2026

Each new clinical case once again confirms that the right decision, made at the right time, can truly change a patient’s outcome.

Another such example recently came from Sofia, Bulgaria, where Efferon was used as part of comprehensive intensive care at University Hospital УМБАЛ "Александровска". After laparotomy, the patient’s condition progressed to septic shock with multiple organ dysfunction and severe hemodynamic instability. When conventional therapy was insufficient, multimodal stabilized hemodynamics and accelerated recovery, allowing discharge in time for the Christmas holidays at home.

Step by step, more hospitals and healthcare systems are gaining access to , and more patients are receiving additional chances when they need them most.

We sincerely thank Assoc. Prof. Yamakova and Dr. Pisanchev for their trust, professionalism, and commitment to bringing efferent practices into daily clinical work.

28/02/2026

Protocol or Clinical Judgment? ICU Doctor Answers

Do we follow strict treatment protocols, or adapt in real time?
In septic shock management, this ICU physician Professor George Dimopoulos follows a focused approach:
Two days.
300 minutes per day.
Then reassess clinical stability.

Because the first 72 hours can define the outcome.

Follow for expert ICU perspectives and critical care discussions.

25/02/2026

¡Hola, Costa Rica! Efferon ya está aquí.

We are proud to announce that Efferon LPS has received official authorization in Costa Rica, becoming the 41st country where next-generation extracorporeal therapy is available!

We are especially pleased to expand our collaboration with US Pharmacy Group, our trusted and highly respected partner across Latin America. With their extensive regional expertise, strong professional network, and deep understanding of local healthcare systems, we are confident that together we will successfully introduce this life-saving technology to healthcare professionals and patients throughout Costa Rica.

Efferon LPS is a next-generation device designed to remove both endotoxins and cytokines from the bloodstream. It has received EU approval for use in sepsis patients under the MDR.